Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

W-J Chng; H Goldschmidt; M A Dimopoulos; P Moreau; D Joshua; A Palumbo; T Facon; H Ludwig; L Pour; R Niesvizky; A Oriol; L Rosiñol; A Suvorov; G Gaidano; T Pika; K Weisel; V Goranova-Marinova; H H Gillenwater; N Mohamed; S Feng; S Aggarwal; R Hájek

doi:10.1038/leu.2016.390

Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

Standard

Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. / Chng, W-J; Goldschmidt, H; Dimopoulos, M A; Moreau, P; Joshua, D; Palumbo, A; Facon, T; Ludwig, H; Pour, L; Niesvizky, R; Oriol, A; Rosiñol, L; Suvorov, A; Gaidano, G; Pika, T; Weisel, K; Goranova-Marinova, V; Gillenwater, H H; Mohamed, N; Feng, S; Aggarwal, S; Hájek, R.

in: LEUKEMIA, Jahrgang 31, Nr. 6, 06.2017, S. 1368-1374.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Chng, W-J, Goldschmidt, H, Dimopoulos, MA, Moreau, P, Joshua, D, Palumbo, A, Facon, T, Ludwig, H, Pour, L, Niesvizky, R, Oriol, A, Rosiñol, L, Suvorov, A, Gaidano, G, Pika, T, Weisel, K, Goranova-Marinova, V, Gillenwater, HH, Mohamed, N, Feng, S, Aggarwal, S & Hájek, R 2017, 'Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR', LEUKEMIA, Jg. 31, Nr. 6, S. 1368-1374. https://doi.org/10.1038/leu.2016.390

APA

Chng, W-J., Goldschmidt, H., Dimopoulos, M. A., Moreau, P., Joshua, D., Palumbo, A., Facon, T., Ludwig, H., Pour, L., Niesvizky, R., Oriol, A., Rosiñol, L., Suvorov, A., Gaidano, G., Pika, T., Weisel, K., Goranova-Marinova, V., Gillenwater, H. H., Mohamed, N., ... Hájek, R. (2017). Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. LEUKEMIA, 31(6), 1368-1374. https://doi.org/10.1038/leu.2016.390

Vancouver

Chng W-J, Goldschmidt H, Dimopoulos MA, Moreau P, Joshua D, Palumbo A et al. Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. LEUKEMIA. 2017 Jun;31(6):1368-1374. https://doi.org/10.1038/leu.2016.390

Bibtex

@article{828bb62559d94ff0a20f1a1c03c9a421,

title = "Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR",

abstract = "The randomized phase 3 study ENDEAVOR demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (MM). We conducted a preplanned subgroup analysis of ENDEAVOR to evaluate Kd vs Vd by cytogenetic risk. Of 785 patients with known cytogenetics, 210 (27%) had high-risk cytogenetics (Kd, n=97 (25%); Vd, n=113 (28%)) and 575 (73%) had standard-risk cytogenetics (Kd, n=284 (75%); Vd, n=291 (72%)). Median PFS in the high-risk group was 8.8 months for Kd vs 6.0 months for Vd (hazard ratio (HR), 0.65; 95% confidence interval (CI), 0.45-0.92; P=0.0075). Median PFS in the standard-risk group was not estimable for Kd vs 10.2 months for Vd (HR, 0.44; 95% CI, 0.33-0.58; P<0.0001). Overall response rates were 72.2% (Kd) vs 58.4% (Vd) in the high-risk group and 79.2% (Kd) vs 66.0% (Vd) in the standard-risk group. In the high-risk group, 15.5% (Kd) vs 4.4% (Vd) achieved a complete response (CR) or better. In the standard-risk group, 13.0% (Kd) vs 7.9% (Vd) achieved ⩾CR. This preplanned subgroup analysis found that Kd was superior to Vd in relapsed or refractory MM, regardless of cytogenetic risk.",

keywords = "Adult, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Bortezomib, Chromosome Aberrations, Cytogenetic Analysis, Dexamethasone, Drug Resistance, Neoplasm, Female, Follow-Up Studies, Humans, Male, Multiple Myeloma, Neoplasm Grading, Neoplasm Recurrence, Local, Oligopeptides, Prognosis, Remission Induction, Salvage Therapy, Survival Rate, Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't",

author = "W-J Chng and H Goldschmidt and Dimopoulos, {M A} and P Moreau and D Joshua and A Palumbo and T Facon and H Ludwig and L Pour and R Niesvizky and A Oriol and L Rosi{\~n}ol and A Suvorov and G Gaidano and T Pika and K Weisel and V Goranova-Marinova and Gillenwater, {H H} and N Mohamed and S Feng and S Aggarwal and R H{\'a}jek",

year = "2017",

month = jun,

doi = "10.1038/leu.2016.390",

language = "English",

volume = "31",

pages = "1368--1374",

journal = "LEUKEMIA",

issn = "0887-6924",

publisher = "NATURE PUBLISHING GROUP",

number = "6",

}

RIS

TY - JOUR

T1 - Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

AU - Chng, W-J

AU - Goldschmidt, H

AU - Dimopoulos, M A

AU - Moreau, P

AU - Joshua, D

AU - Palumbo, A

AU - Facon, T

AU - Ludwig, H

AU - Pour, L

AU - Niesvizky, R

AU - Oriol, A

AU - Rosiñol, L

AU - Suvorov, A

AU - Gaidano, G

AU - Pika, T

AU - Weisel, K

AU - Goranova-Marinova, V

AU - Gillenwater, H H

AU - Mohamed, N

AU - Feng, S

AU - Aggarwal, S

AU - Hájek, R

PY - 2017/6

Y1 - 2017/6

N2 - The randomized phase 3 study ENDEAVOR demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (MM). We conducted a preplanned subgroup analysis of ENDEAVOR to evaluate Kd vs Vd by cytogenetic risk. Of 785 patients with known cytogenetics, 210 (27%) had high-risk cytogenetics (Kd, n=97 (25%); Vd, n=113 (28%)) and 575 (73%) had standard-risk cytogenetics (Kd, n=284 (75%); Vd, n=291 (72%)). Median PFS in the high-risk group was 8.8 months for Kd vs 6.0 months for Vd (hazard ratio (HR), 0.65; 95% confidence interval (CI), 0.45-0.92; P=0.0075). Median PFS in the standard-risk group was not estimable for Kd vs 10.2 months for Vd (HR, 0.44; 95% CI, 0.33-0.58; P<0.0001). Overall response rates were 72.2% (Kd) vs 58.4% (Vd) in the high-risk group and 79.2% (Kd) vs 66.0% (Vd) in the standard-risk group. In the high-risk group, 15.5% (Kd) vs 4.4% (Vd) achieved a complete response (CR) or better. In the standard-risk group, 13.0% (Kd) vs 7.9% (Vd) achieved ⩾CR. This preplanned subgroup analysis found that Kd was superior to Vd in relapsed or refractory MM, regardless of cytogenetic risk.

AB - The randomized phase 3 study ENDEAVOR demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (MM). We conducted a preplanned subgroup analysis of ENDEAVOR to evaluate Kd vs Vd by cytogenetic risk. Of 785 patients with known cytogenetics, 210 (27%) had high-risk cytogenetics (Kd, n=97 (25%); Vd, n=113 (28%)) and 575 (73%) had standard-risk cytogenetics (Kd, n=284 (75%); Vd, n=291 (72%)). Median PFS in the high-risk group was 8.8 months for Kd vs 6.0 months for Vd (hazard ratio (HR), 0.65; 95% confidence interval (CI), 0.45-0.92; P=0.0075). Median PFS in the standard-risk group was not estimable for Kd vs 10.2 months for Vd (HR, 0.44; 95% CI, 0.33-0.58; P<0.0001). Overall response rates were 72.2% (Kd) vs 58.4% (Vd) in the high-risk group and 79.2% (Kd) vs 66.0% (Vd) in the standard-risk group. In the high-risk group, 15.5% (Kd) vs 4.4% (Vd) achieved a complete response (CR) or better. In the standard-risk group, 13.0% (Kd) vs 7.9% (Vd) achieved ⩾CR. This preplanned subgroup analysis found that Kd was superior to Vd in relapsed or refractory MM, regardless of cytogenetic risk.

KW - Adult

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Biomarkers, Tumor

KW - Bortezomib

KW - Chromosome Aberrations

KW - Cytogenetic Analysis

KW - Dexamethasone

KW - Drug Resistance, Neoplasm

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Male

KW - Multiple Myeloma

KW - Neoplasm Grading

KW - Neoplasm Recurrence, Local

KW - Oligopeptides

KW - Prognosis

KW - Remission Induction

KW - Salvage Therapy

KW - Survival Rate

KW - Clinical Trial, Phase III

KW - Comparative Study

KW - Journal Article

KW - Multicenter Study

KW - Randomized Controlled Trial

KW - Research Support, Non-U.S. Gov't

U2 - 10.1038/leu.2016.390

DO - 10.1038/leu.2016.390

M3 - SCORING: Journal article

C2 - 28025582

VL - 31

SP - 1368

EP - 1374

JO - LEUKEMIA

JF - LEUKEMIA

SN - 0887-6924

IS - 6

ER -